Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 364

1.

Safety profile of orlistat: results of a prescription-event monitoring study.

Acharya NV, Wilton LV, Shakir SA.

Int J Obes (Lond). 2006 Nov;30(11):1645-52. Epub 2006 Mar 21.

PMID:
16552401
2.

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

Perrio MJ, Wilton LV, Shakir SA.

Obesity (Silver Spring). 2007 Nov;15(11):2712-22.

3.

The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.

Biswas PN, Wilton LV, Shakir SW.

J Hum Hypertens. 2002 Nov;16(11):795-803.

4.

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.

Boshier A, Wilton LV, Shakir SA.

Eur J Clin Pharmacol. 2003 Dec;59(10):767-73. Epub 2003 Nov 13.

PMID:
14615857
5.

Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.

Layton D, Clarke A, Wilton LV, Shakir SA.

Osteoporos Int. 2005 May;16(5):490-500. Epub 2004 Aug 7.

PMID:
15309382
6.
7.
8.

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

Barrera BA, Wilton L, Harris S, Shakir SA.

Osteoporos Int. 2005 Dec;16(12):1989-98. Epub 2005 Aug 31.

PMID:
16133643
9.

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.

Twaites B, Wilton LV, Layton D, Shakir SA.

Acta Diabetol. 2007 Dec;44(4):233-9. Epub 2007 Sep 15.

PMID:
17874223
10.
11.
12.

Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.

Schwartz SM, Bansal VP, Hale C, Rossi M, Engle JP.

Obesity (Silver Spring). 2008 Mar;16(3):623-9. doi: 10.1038/oby.2007.96. Epub 2008 Jan 24.

13.

The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.

Twaites BR, Wilton LV, Shakir SA.

J Psychopharmacol. 2007 Jun;21(4):392-9. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699. J Psychopharmacol. 2007 Sep;21(7):783.

PMID:
17656426
14.
15.

Safety profile of oxcarbazepine: results from a prescription-event monitoring study.

Buggy Y, Layton D, Fogg C, Shakir SA.

Epilepsia. 2010 May;51(5):818-29. doi: 10.1111/j.1528-1167.2009.02489.x. Epub 2010 Feb 3.

16.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
17.

The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.

Hazell L, Cornelius V, Wilton LV, Shakir SA.

BJU Int. 2009 Feb;103(4):506-14. doi: 10.1111/j.1464-410X.2008.08000.x. Epub 2008 Oct 16.

18.

Safety profile of nicorandil--prescription-event monitoring (PEM) study.

Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD.

Pharmacoepidemiol Drug Saf. 1999 May;8(3):197-205.

PMID:
15073929
20.

Pharmacovigilance study of alendronate in England.

Biswas PN, Wilton LV, Shakir SA.

Osteoporos Int. 2003 Jul;14(6):507-14. Epub 2003 Apr 23.

PMID:
12730757

Supplemental Content

Support Center